The thiazide-sensitive NaCl cotransporter (NCC) of the renal distal convoluted tubule (DCT) controls ion homeostasis and arterial BP. Loss-of-function mutations of NCC cause renal salt wasting with arterial hypotension (Gitelman syndrome). Conversely, mutations in the NCC-regulating WNK kinases or kelchlike 3 protein cause familial hyperkalemic hypertension. Here, we performed automated sorting of mouse DCTs and microarray analysis for comprehensive identification of novel DCT-enriched gene products, which may potentially regulate DCT and NCC function. This approach identified protein phosphatase 1 inhibitor-1 (I-1) as a DCT-enriched transcript, and immunohistochemistry revealed I-1 expression in mouse and human DCTs and thick ascending limbs. In heterologous expression systems, coexpression of NCC with I-1 increased thiazide-dependent Na + uptake, whereas RNAi-mediated knockdown of endogenous I-1 reduced NCC phosphorylation. Likewise, levels of phosphorylated NCC decreased by approximately 50% in I-1 (I-1 2/2 ) knockout mice without changes in total NCC expression. The abundance and phosphorylation of other renal sodium-transporting proteins, including NaPi-IIa, NKCC2, and ENaC, did not change, although the abundance of pendrin increased in these mice. The abundance, phosphorylation, and subcellular localization of SPAK were similar in wild-type (WT) and I-1 2/2 mice. Compared with WT mice, I-1 2/2 mice exhibited significantly lower arterial BP but did not display other metabolic features of NCC dysregulation. Thus, I-1 is a DCT-enriched gene product that controls arterial BP, possibly through regulation of NCC activity.
The distal convoluted tubule (DCT) plays a pivotal role in the renal control of ion homeostasis and BP. 1 The DCT reabsorbs approximately 10% of the filtered NaCl load and is significantly involved in renal potassium (K + ), calcium, magnesium, and acid/ base handling. 1 The thiazide-sensitive NaCl cotransporter (NCC) is the major apical sodium (Na + ) transport pathway in the DCT. In the late DCT, NCC abundance overlaps with the expression of the epithelial sodium channel (ENaC), which is the apical sodium reabsorption pathway in the connecting tubule and collecting duct. NCC activity and hence, DCT salt transport are regulated by a variety of factors, including dietary ion intake, plasma hormones (e.g., aldosterone, angiotensin II, and vasopressin), and metabolic factors (e.g., alkalosis). 1, 2 Several human tubulopathies (genetic and acquired) have been attributed to dysfunctions of the DCT. Loss-of-function mutations of NCC (Gitelman syndrome) cause renal salt wasting with hypotension, hypokalemic alkalosis, and hypocalciuria, 3 whereas increased NCC activity because of mutations within the NCC-regulating with-no-lysine kinase 1 (WNK1) or WNK4 (familial hyperkalemic hypertension) are associated with severe salt-sensitive hypertension, hyperkalemia, metabolic acidosis, and hypercalciuria. 4 Increased NCC expression has been linked to renal Na + retention in liver cirrhosis, 5 diabetes mellitus, 6 b-adrenergic stimulation, 7 and immunosuppressive treatment. 8 The clinical significance of the DCT is also emphasized by clinical trials that confirmed the DCT as an important target for antihypertensive therapy. 9 The identification of the WNKs as regulators of NCC 4 was key for our current understanding of the molecular mechanisms that control NCC. WNK1 and WNK4 are serine/ threonine kinases that interact in a complex cascade with the STE20-related proline-alanine-rich kinase (SPAK) to regulate NCC phosphorylation (e.g., Thr44, Thr53, Thr58, and Ser71 in mouse NCC) and finally, activity. 8, [10] [11] [12] In addition to the WNK-SPAK pathway, several other proteins were identified to control NCC, including parvalbumin (PV), 13 serum and glucocorticoid-inducible kinase Sgk1, ubiquitin ligase Nedd4-2, [14] [15] [16] kelch-like 3 (KLHL3), 17, 18 cullin 3, 17,18 and protein phosphatase (PP) 4. 19 Remarkably, several of the above listed regulatory proteins are highly abundant in the DCT (e.g., WNK4, KS-WNK1, SPAK, PV, and KLHL3). Therefore, we hypothesized that the DCT may express a particular set of DCT-enriched gene products, of which at least some participate in the regulation of NCC-mediated sodium absorption. Encouraged by previous gene expression analysis on freehand-isolated renal tubules in the works by Chabardès-Garonne et al., 20 Cheval et al., 21 and Pradervand et al., 22 we aimed at identifying DCT-enriched gene products using a transcriptomic approach. We used complex object parametric analysis and sorting (COPAS) of renal tubules, which was developed by Miller et al., 23 to isolate DCTs on a large scale. Among others, we identified the PP1 inhibitor-1 (I-1) to be highly enriched in the DCT. I-1 is encoded by the Ppp1r1a gene and forms a small, 171-aa-long cytosolic protein 24 that was the first identified endogenous inhibitor of PP1. 25 Here we show that I-1 affects the phosphorylation of NCC in vitro and in vivo. I-1 deficiency reduces NCC phosphorylation and lowers arterial BP in mice.
RESULTS

Identification of DCT-Enriched Genes
For large-scale isolation of mouse DCTs by COPAS, we used a transgenic mouse model expressing the enhanced green fluorescent protein (EGFP) under the control of the PV promoter (PV-EGFP). 26 Immunofluorescent labeling of kidney cryosections from these mice confirmed the orthotopic expression of EGFP in the PV-positive early DCTs but not the ENaC-positive late DCTs (Figure 1, A and B) . Kidneys of these mice were digested with collagenase and processed for COPAS as described in Concise Methods. Fluorescent emission and time of flight (as an indicator of tubule size) for each tubule fragment were plotted ( Figure 1C) . A selection window for sorting was set to collect three separate fractions, namely EGFP-positive tubules (EGFP + ), EGFP-negative tubules (EGFP 2   ) , and all types of tubules (ALL) ( Figure 1C) . Subsequent analysis of gene expression and protein abundance confirmed a strong enrichment of DCT cells in the EGFP + samples (Figure 1, D and E) . The DCT-specific NCC was highly enriched in the EGFP + samples compared with all tubules, whereas markers for proximal tubules (sodium-dependent phosphate cotransporter IIa [NaPi-IIa]), thick ascending limbs (sodium-potassium-2-chloride cotransporter-2 [NKCC2]), and connecting tubules and collecting ducts (AQP2) were almost absent from the EGFP + fraction. The weak band for bENaC ( Figure 1E ) likely relates to slight contaminations of early DCT samples, with attached late DCTs expressing bENaC. 27 To identify DCT-enriched gene products, we performed comparative transcriptome analysis of sorted EGFP + , EGFP 2 , and ALL fractions using Whole Mouse Genome Microarrays (Agilent Technologies). EGFP + /ALL and ALL/EGFP 2 expression ratios were determined for each gene product. The known DCT markers PV, 27 transient receptor potential-melastatin 6 (TRPM6), 28 and NCC 29 are strongly enriched in EGFP + samples but absent from the EGFP 2 samples (Supplemental Table 1 ). In contrast, gene expression for proximal tubule markers, such as aquaporin-1, NaPi-IIa, and megalin, was almost absent in the EGFP + fraction compared with the ALL tubule sample (Supplemental Table 1 ). To define DCT-enriched genes, the EGFP + /EGFP 2 ratio was calculated for each gene. The 100 genes with the most prominent DCT enrichment are presented in Supplemental Table 2 .
Among these genes, we found known regulators of NCC, such as PV, 13 KLHL3, 17, 18 and WNK1, 30 with EGFP + /EGFP 2 ratios of 935, 36, and 35, respectively (Supplemental Table 2 ). Although not among the first 100 gene products, WNK4 and SPAK are also significantly enriched in the EGFP + versus EGFP 2 fraction (ratios of 22 and 13, respectively). We then analyzed the list specifically for gene products that may interact with or counterbalance the action of these kinases. In this regard, I-1, which is markedly enriched (EGFP + /EGFP 2 ratio of 47) in DCT, was found to be an interesting candidate. Figure 2C ). Detailed analysis of consecutive cryosections stained with antibodies against I-1, NCC, and calbindin D28k (CB28K) showed that I-1 protein is highly abundant in the cytoplasm of NCC-and CB28K-positive DCT cells. I-1 is also abundant in the preceding cortical ( Figure 2D ) and medullary thick ascending limb (TAL) (not shown). A similar distribution pattern was revealed in human kidneys (Supplemental Figure 1) .
I-1 Regulates NCC Phosphorylation
To test the possible role of I-1 in controlling NCC phosphorylation, I-1 RNA interference knockdown experiments were performed in human embryonic kidney (HEK) cells stably expressing NCC 8 ( Figure 3A ). We first showed that HEK cells exhibit endogenous I-1 and its target PP1. Knockdown of I-1 by small interfering RNA substantially reduced the abundance of NCC phosphorylated at Thr53 but not the total abundance of NCC. These results suggest that I-1 is part of a novel pathway controlling NCC phosphorylation. To test for functional effects, we injected Xenopus oocytes with cRNAs encoding NCC together with PP1a, the catalytic subunit of PP1, or a constitutively active variant of I-1 (T35D). 31 I-1 (T35D) substantially increased 22 Na uptake ( Figure 3B ). PP1a slightly reduced 22 Na uptake, but the differences did not reach statistical significance. The heterologous overexpression of PP1a may not have been sufficient to overcome the known high activity of endogenous PP1 in the oocyte. 32 To confirm that I-1 can exert similar effects in vivo, we analyzed NCC phosphorylation in kidneys of WT and I-1 2/2 mice using antibodies against total NCC and NCC phosphorylated at Thr53, Thr58, Ser71, and Ser89. 33 Similar to the results in HEK293 cells, total NCC abundance was similar in WT and I-1 2/2 kidneys, whereas the phosphorylation of NCC at all analyzed phosphorylation sites was significantly reduced ( Figure 3 , C and D).
Lower BP in I-1 2/2 Mice NCC plays an important role in BP regulation, which is evidenced by high or low BP in mice with activated or suppressed NCC, respectively. 2,11,12 Therefore, we hypothesized that I-1 deficiency should lower BP. Indeed, I-1 2/2 mice have significantly lower systolic BP than WT mice on both standard (0.8% Na + ) and low Na + (0.05% Na + ) diets ( Figure 4A ).
I-1 2/2 Mice Manifest Features of Mild NCC Deficiency
To determine whether I-1 2/2 mice exhibit metabolic features suggesting NCC dysfunction, we performed metabolic studies. On standard diet, blood ion concentrations, blood pH, blood bicarbonate, and urinary ion excretion rates were similar to the values in WTmice (Tables 1 and 2 ). Likewise, plasma aldosterone levels and urinary aldosterone excretion were similar for WT and I-1 2/2 mice. Even on a low Na + diet, I-1
mice could rapidly reduce their urinary Na + excretion ( Figure  4B ), and urinary ion and aldosterone excretion did not differ between genotypes, even after 14 days of Na + restriction (Table  2) . Nevertheless, on both standard and low Na + diets, I-1-deficient mice tended to have lower plasma K + levels than WT mice. NCC 2/2 mice must be challenged with dietary K + deprivation to exhibit frank hypokalemia. 34 Therefore, we fed WT and I-1 2/2 mice a low K + diet (0.05% K + ) for 4 days. In contrast to the NCC 2/2 mice, 34 I-1 2/2 mice were able to reduce urinary K + excretion similar to WT mice ( Figure 4C ). Plasma K + values remained lower in I-1 2/2 than WTmice, but differences still did not reach statistical significance ( Figure  4D ). To further test for the in vivo activity of NCC, we performed a hydrochlorothiazide (HCTZ) test. WT and I-1 2/2 mice were injected with either vehicle or HCTZ; urinary Na + excretion was measured for the subsequent 6 hours and expressed as the differences between thiazide-and vehicle-induced natriuresis. Statistical differences between genotypes were not detected on either standard or low Na + diet ( Figure 4E ). Nevertheless, on low Na + diet, I-1 2/2 mice had a tendency for a decreased HCTZ response (P=0.08 unpaired t test, WT versus I-1 2/2 ).
Compensatory Upregulation of Pendrin in I-1 2/2 Mice To test whether upregulation of other ion transport pathways may compensate for reduced NCC phosphorylation and activity, we analyzed the abundance of several Na + transporting proteins expressed along the nephron ( Figure 4F , Supplemental Table 3 ). The abundance of the NaPi-IIa of proximal tubules, the NKCC2 of thick ascending limbs, and the ENaC and the sodium-driven bicarbonate-chloride exchanger of principal and intercalated cells in the renal collecting system (i.e., connecting tubule and collecting duct) were not altered in kidneys of WT versus I-1 2/2 mice. However, pendrin, the apical bicarbonate-chloride exchanger in nontype A intercalated cells, was found to be more abundant in kidneys of I-1 2/2 than WT mice ( Figure 4F , Supplemental Table 3 ).
I-1 Deficiency Does Not Affect NKCC2 Phosphorylation
Because I-1 is also expressed in the TAL and because NKCC2 is homologous to NCC, we looked more specifically to the effect of I-1 deficiency on NKCC2 in an additional set of mice. By IB and IHC, we could not detect any significant differences between WT and I-1 2/2 mice for the abundance and subcellular localization of total NKCC2 and phospho-NKCC2 (Figure 5 , A-C). To further exclude any downregulation of NKCC2, we performed a furosemide test. Interestingly, the Immunostaining of consecutive cryosections from WT mice shows a cytoplasmic I-1 localization in NCC-and CB28K-positive early DCTs (D1; no or weak CB28K) and late DCTs (D2; strong CB28K) and in the NCC-negative TAL (T). Scale bars, ;20 mm.
natriuretic response to furosemide was even increased in I-1 2/2 mice ( Figure 5D ). Because I-1 2/2 mice have a lowered BP and an unchanged NKCC2 phosphorylation, this response is unlikely related to an increased NKCC2 function, but rather, it is consistent with the reduced NCC activity in I-1 2/2 mice, which perhaps lowered the capacity of the DCT to absorb the furosemide-induced sodium load.
I-1 Deficiency Does Not Affect SPAK Phosphorylation SPAK is thought to represent the final step in the WNK pathway controlling NCC phosphorylation. To test whether I-1 may interfere with the WNK/SPAK pathway, we analyzed the abundance, phosphorylation, and subcellular localization of SPAK in kidneys of WT and I-1 2/2 mice using antibodies directed against total SPAK and SPAK phosphorylated at Ser373. Neither the total abundance nor the phosphorylation level of SPAK was different between WT and I-1 2/2 mice, which were assessed by IB and IHC ( Figure 6 ). Likewise, mRNA expression of the upstream SPAK regulators WNK4 and kidney-specific WNK1 were not different between genotypes (Supplemental Table 4 ).
DISCUSSION
The shortness and hidden localization of the DCT in the renal labyrinth complicate analyses of DCT function and underlying regulatory mechanisms. Using freehand microdissection, previous studies established transcriptome data for the renal distal convolution, 21, 22 but the gradual transition from the DCT to the connecting tubule makes it almost impossible to precisely define the border between these functionally different segments. Moreover, the low yield of microdissection requires amplification of obtained cDNAs, which bears the risk of increased false-positive and false-negative results. In the present study, we combined the early DCT specificity of PV-EGFP expression with the high yield of COPAS to obtain rather pure DCT preparations on a large scale without the need for any further cDNA amplification. IB and transcriptomic analysis confirmed the high degree of purity of the isolated DCT samples. Differential hybridization and analysis of ALL, EGFP 2 , and EGFP + tubules further confirmed the reliability of our approach and permitted us to identify DCTenriched gene products. As expected, the known DCT-specific genes NCC, TRPM6, and PV showed the most significant enrichment in our DCT preparations. Other than these three strongly enriched genes, about 300 other genes were found to be more than 10-fold enriched in the DCT. Among these DCTenriched genes are the known NCC regulators SPAK, 35 Mean6SEM (n=7). Statistical significance was calculated with unpaired t test (*P,0.05; ***P,0.001).
WNK4, 36 KS-WNK1, 30 and KLHL-3. 17, 18 Interestingly, several of the other DCTenriched genes are known to be involved in the control of cell growth and differentiation during development (e.g., Sfrp1, Sox9, Lrrn1, Prox1, and Sall3). The high expression levels of these developmental genes in the adult DCT may relate to the particular structural plasticity of the DCT to growth stimuli. 37 NCC is activated by phosphorylation through the WNK-SPAK pathway. 35 Usually, the activity of kinases is counterbalanced by phosphatases. Prior studies suggested that PP4 regulates NCC. 19 Here we report that PP1, PP2, and PP3 are also highly expressed in DCT cells. The specificity and catalytic activity of phosphatases are modulated by the interaction with specific regulatory and inhibitory subunits. 38 In this study, we identified the I-1 to be highly enriched in the mouse and human DCTs as well as the TAL. The latter is consistent with previous data that showed a localization of I-1 in the medullary and cortical TALs. 39,40 I-1 is also expressed in brain, skeletal muscle, and heart, where it is thought to contribute to synaptic plasticity, 41 muscle glycogen metabolism, 42 and cardiac contractility and excitability. 24 Using three independent experimental systems, we now provide evidence that I-1 also regulates renal NCC function. In Xenopus laevis oocytes, coexpression of I-1 and NCC profoundly increases thiazidesensitive Na + uptake, whereas knockdown of I-1 in HEK293 cells as well as I-1 deficiency in mice led to a pronounced reduction in NCC phosphorylation. The similarity of the data in the HEK293 cells in vitro and the kidney in vivo indicates that the reduced NCC phosphorylation is a cellautonomous effect of I-1 deficiency. We have recently shown that ex vivo incubation of DCTs with the PP1 and PP2a inhibitor calyculin A drastically increases NCC phosphorylation. 33 Given that I-1 is a rather specific inhibitor of PP1 with no effects Figure 4 . I-1 deficiency lowers arterial blood pressure but has little or no effect on Na + , on PP2a and PP2b (also called PP3), 38 it is tempting to speculate that the observed effects of I-1 are mediated by PP1. Consistent with an involvement of PP1 in NCC regulation, preliminary yeast two-hybrid and coimmunoprecipitation data indicated that PP1 physically interacts with NCC (R.A.F., unpublished observations). In the oocyte expression system, PP1 was shown to also control NKCC1. 43 The effect on NKCC1 seemed to be mediated by both direct dephosporylation of the transporter and dephosphorylation of NKCC1-activating SPAK. In our study, we did not test by which mechanism I-1 controls NCC dephosphorylation, but the unchanged phosphorylation levels of SPAK1 in I-1 2/2 mice indicate that I-1 does not exert its effects through reducing phosphorylation and activation of the SPAK pathway.
Interestingly, although I-1 is also highly abundant in the TAL, I-1 2/2 mice do not show any significant effect on the phosphorylation levels of NKCC2. The TAL expresses it in addition to I-1 high levels of another endogenous PP1 inhibitor named DARPP-32 (Ppp1r1b), 39, 40 which may compensate for the loss of I-1 in the TAL.
I-1 deficiency does not completely abrogate NCC phosphorylation in the kidney. The maintenance of a certain level of NCC phosphorylation may explain the rather mild phenotype of the I-1 2/2 mice. In contrast to patients with Gitelman syndrome and NCC-deficient mice as well as NCC knock-in mice bearing a Gitelman mutation (Ser707/X) 44 and SPAKdeficient mice, 45 ,46 the I-1 2 /2 mice have no secondary hyperaldosteronism, hypomagnesaemia, and hypocalciuria. However, I-1 2/2 mice tend to have a reduced thiazide response on dietary Na + restriction and a trend for slightly lowered plasma K + concentrations. Moreover, they have a lower BP on standard and low Na + diet. As such, the phenotype resembles the one seen in SPAK +/2 mice, which also have reduced NCC phosphorylation levels and arterial hypotension without any significant abnormalities for plasma and urine electrolytes, plasma aldosterone, and thiazide response. 46 Likewise, NCC +/2 mice (D.L.-C., unpublished observation) and humans heterozygous for NCC mutations have low BP 47 without frank Gitelman disease. 48 Also, thiazides are known to efficiently reduce BP without provoking obvious extracellular volume depletion in many patients. 49 However, because I-1 is expressed in heart and arterial vessels, we cannot rule out that the lowered BP in I-1 2/2 mice is of extrarenal origin, although previous studies reported only rather small (if any) effects of I-1 deficiency on heart ejection fraction and no effects on aortic contractility. 50 Another reason for the mild phenotype of I-1 2/2 mice could be rooted in the compensatory upregulation of other ion transporting pathways along the nephron. Previous studies suggest that NCC 2/2 mice compensate, in part, by activating the epithelial sodium channel ENaC. 51, 52 Moreover, NCC 2/2 mice exhibit an enhanced abundance of the bicarbonatechloride cotransporter pendrin, 53 which when deleted in NCC 2/2 mice, led to lethal salt wasting. 54 Consistent with the unchanged aldosterone levels in I-1 2/2 mice, we did not detect any evidence for an altered ENaC regulation. However, the pendrin protein abundance was found to be upregulated, which could have contributed to the compensated phenotype.
The inhibitory action of I-1 on PP1 depends on protein kinase A-mediated phosphorylation of I-1 at a threonine residue at position 35. 24,38 The DCT is target for several hormones that use cAMP and protein kinase A as signaling molecules. 55 Future work will have to establish how much I-1 participates in the hormonal control of NCC and which molecular mechanism might be involved. Moreover, it remains elusive if I-1 in the kidney also regulates the function of proteins other than NCC.
In conclusion, our study provides proof of concept that the search for DCT-enriched genes may reveal novel regulators of DCTand NCC function, although enrichment in the DCT does not necessarily mean that the gene product is of major importance and it may not have multiple functions and targets in the DCT cells. In this study, we identified the phosphatase inhibitor I-1 as a DCT-enriched gene product and a novel molecular player controlling the phosphorylation of NCC in vitro and in vivo. Loss of I-1 expression lowers arterial BP without other cardinal features of complete NCC deficiency, such as hypokalemic alkalosis and hypomagnesemia. As such, I-1 deficiency resembles the phenotype seen in human heterozygotes for NCC mutations, which also have reduced BP, 47 but no other symptoms characteristic of Gitelman syndrome. 48 Because several patients with a full Gitelman phenotype have only one or even no alleles with NCC mutations, it might be interesting to analyze these patients for mutations in I-1 or other identified DCT-enriched genes. Thus, I-1 represents a new gene involved in regulation of NCC and BP that might be affected in hereditary and acquired renal tubulopathies.
CONCISE METHODS
Animals
For COPAS sorting, we used adult (10-12 weeks old) male and female PV-EGFP transgenic mice. 26 I-1-deficient mice were a gift from P. Greengard. 41 Both mouse strains were kept in a homogenetic C57BL/6J background. All mice were maintained on a standard rodent diet with free access to food and water. For diet experiments, mice were kept on semisynthetic diets (Sniff, Soest, Germany) with either low sodium (0.05% Na + ) or low potassium (0.05% K + ) concentrations. For the control groups, NaCl or KCl was supplemented to these diets to reach either standard sodium (0.3% Na + ) or standard potassium (0.8% K + ) contents. For blood sampling and organ harvesting, mice were anesthetized with a mixture of Ketamine (Narketan 10, 80 mg/kg body wt; Chassot, Belp, Switzerland) and Xylazine (Rompun, 33 mg/kg body wt; Bayer, Leverkusen, Germany). Daily urine sampling on different diets was performed in metabolic cages (Tecniplast, Buguggiate, Italy). Mice were kept on the diets for at least 14 days. All animal experiments were performed according to Swiss Animal Welfare laws, with approval of the local veterinary authority (Kantonales Veterinäramt Zürich).
COPAS Sorting and Microarray Analysis of Sorted DCT
Supplemental Materials and Methods has a detailed description of the protocol. COPAS sorting was adapted from the work by Miller et al. 23 The microarray data were deposited in the National Center for Biotechnology Information Gene Expression Omnibus database (accession number GSE51935).
Hydrochlorothiazide and Furosemide Treatment
WTand I-1 2/2 mice were kept for 14 days on 0.3% Na + or 0.05% Na + diet and then placed in metabolic cages. At day 4 in the metabolic cage, each mouse received a single intraperitoneal injection of vehicle (1:1 mixture of 0.9% NaCl solution with methanol or polyethylenglycol 300 for 0.3% Na + or 0.05% Na + diet, respectively), and urine was collected for the next 6 hours; 24 hours later, mice received either HCTZ (50 mg/kg; Sigma-Aldrich) or furosemide (Furo, 40 mg/kg; Sigma-Aldrich), and urine was collected again for a 6-hour period.
Biochemical Measurements
Blood gas and blood ions were measured with the ABL825Flex Blood Gas Analyzer (Radiometer, Copenhagen, Denmark). Blood magnesium was measured by atomic absorption spectrophotometry (PerkinElmer Apparatus, Model 3110; PerkinElmer, Cortabeuf, France). Plasma and urine aldosterone levels were measured with a radioimmunoassay using commercially available kits (DRG Diagnostics, Marburg, Germany, and DPC Dade Behring, La Défense, France, respectively). Urinary creatinine was assessed by the Jaffe method. Urinary electrolytes (Na + , K + , and Ca 2+ ) were measured by ion chromatography (Metrohm Ion Chromatograph, Herisau, Switzerland).
BP Recordings
Systolic BP was recorded on conscious mice using the noninvasive tailcuff method (Visitech). Mice were habituated to the instrument for 4 consecutive days. Then, BP was measured daily between 10:00 and 
IHC
Mouse kidneys were fixed by vascular perfusion of 3% paraformaldehyde in phosphate buffer and processed for immunohistochemistry as described. 56 Human kidney samples were archived tissue. Cryosections were analyzed with a Leica fluorescence microscope. Cryosections were examined with a fluorescence microscope (Leica DM6000B). Images were acquired with a charge-coupled device camera and processed by Adobe Photoshop CS3.
IB
Membrane protein fractions were prepared, resolved on SDS polyacrylamide gels, and blotted on nitrocellulose membranes. 57 Binding of the primary antibody was visualized using Infra Red Dye-conjugated secondary antibodies (LI-COR Biosciences) and an Odyssey infrared-scanner detection system (LI-COR Biosciences).
Antibodies
Primary and secondary antibodies were diluted for IHC and IB in PBS with 0.1% BSA and LI-COR Blocking Buffer, respectively. Antibodies used were rabbit anti-I-1 (IHC: 1/1000, IB: 1/20,000; Epitomics), rabbit anti-NaPi-IIa (IB: 1/5000), 58 rabbit anti-NKCC2 (IB: 1/10,000), 56 rabbit anti-total NCC 27 (IHC: 1/8000), rabbit anti-total NCC 58 (IB: 1/2000), rabbit anti-phospho-Thr53 NCC 57 (IB: 1/5000), rabbit anti-phospho-Thr58 NCC 58 (IB: 1/5000), rabbit anti-phospho-Ser71 NCC 58 (IB: 1/10,000), rabbit anti-phosphoSer89 NCC 58 (IB: 1/10,000), mouse anti-CB28K (IHC: 1/20,000; Swant, Bellinzona, Switzerland), rabbit anti-aENaC 58 (IHC and IB: 1/10,000), rabbit anti-bENaC (IB: 1/40,000) 56 , anti-gENaC 56 (IB: 1/20,000), rabbit anti-pendrin 59 (IB: 1/5000), rabbit anti-sodiumdriven bicarbonate-chloride exchanger 60 (IB: 1/500), rabbit anti-SPAK (IHC and IB: 1/500, 07-2271; Milipore), and rabbit anti-human phospho-SPAK (Ser373; IHC and IB: 1/500, 07-2273; Milipore). For detection of phosphorylated NKCC2, we used a novel rabbit phosphoform-specific antibody (IHC and IB: 1/500). The antiserum against rat NKCC2 phosphorylated at T96 and T101 was generated by immunizing rabbits with the following phosphorylated peptide: QT P FGHNT P MC by Genscript. The C-terminal cysteine was added for conjugation to carrier protein and attachment of the peptide to the affinity purification column for subsequent affinity purification of the antisera against the phospho-and the corresponding nonphosphopeptide. Secondary antibodies were goat anti-rabbit IgG coupled to Alexa 555 dye (1/2000; Invitrogen), goat anti-mouse IgG coupled to Alexa 488 dye (1/1000; Molecular Probes), and donkey anti-sheep IgG coupled to IRDye 800CW (1/20,000; Rockland, Gilbertsville, PA). The characterization of the novel antibody against phosphorylated NKCC2 is shown in Supplemental Figure 2 . The specificity of the antibodies for phosphorylated NCC forms was confirmed by dephosphorylation of tissue homogenates and using kidneys of NCCdeficient mice as negative controls (Supplemental Figure 3) . The SPAK and pSPAK antibodies were characterized by comparing their binding patterns with total lysates of isolated DCTs and whole-mouse kidneys. The phosphoform specificity of the pSPAK antibody was confirmed by using dephosphorylated kidney protein homogenates (Supplemental Figure 4 ).
HEK293 Cells with Inducible NCC Expression Cells
The Flp-In T-REx HEK NCC cell line, which was described previously, 8 is maintained in high-glucose DMEM containing 10% vol/vol FBS, 200 mg/ml hygromycin, 15 mg/ml blasticidin, and penicillin/ streptomycin. NCC is induced by incubating the cells with tetracycline (1 mg/ml) followed by cell lysis and IB. To knock down endogenous I-1 expression, HEK cells were transfected using Lipofectamine 2000 (Invitrogen) with 20-40 nM I-1 small interfering RNA oligonucleotides (59-CCACATCTAAGTCCACTT; Invitrogen) according to the manufacturer's protocol.
Oocyte Experiments
The uptake of 22 Na was performed as described previously. 61 T7 RNA polymerase (mMESSAGE mMACHINE; Ambion) was used to make cRNA. Sorted Xenopus oocytes were injected with 50 nl water containing 5 ng NCC with or without 5 ng PP1a and constitutive active I-1 (ppp1r1a) T35D variant, which is noted in the figures. For each experimental condition, 10-20 oocytes were injected; 3 days after injection, oocytes were incubated in chloride-free medium for 3-4 hours at 18°C before Na uptake was measured. The n value given in the figures represents the number of independent experiments.
